Skip to Main Content

A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) Tablet for 12 weeks in Genotype 1 or 4 HCV-Infected

Principal Investigator

Paul Martin

Clinical Trial ID

Institutional Protocol # 20130597

Clinical Trial Summary


Phase II

Funding Agency/Sponsor



Hepatitis C

Contact Information

Study Contact Eliana Mendes
Phone Number 305-243-2647